AK098656: a new biomarker of coronary stenosis severity in hypertensive and coronary heart disease patients

Xin Wang; Ya-Li Wu; Yuan-Yuan Zhang; Jing Ke; Zong-Wei Wang; Bao-Yu Zhang; Yan Ma; Long-Yan Yang; Dong Zhao

doi:10.1186/s13098-022-00783-3

AK098656: a new biomarker of coronary stenosis severity in hypertensive and coronary heart disease patients

Diabetol Metab Syndr. 2022 Jan 15;14(1):10. doi: 10.1186/s13098-022-00783-3.

Authors

Xin Wang^#^{1

2}, Ya-Li Wu^#^{1

2}, Yuan-Yuan Zhang^{1

2}, Jing Ke^{1

2}, Zong-Wei Wang^{1

2}, Bao-Yu Zhang^{1

2}, Yan Ma^{1

2}, Long-Yan Yang^{3

4}, Dong Zhao^{5

6}

Affiliations

¹ Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
² Beijing Key Laboratory of Diabetes Research and Care, Beijing, China.
³ Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China. lingbeiyangstudent@163.com.
⁴ Beijing Key Laboratory of Diabetes Research and Care, Beijing, China. lingbeiyangstudent@163.com.
⁵ Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China. zhaodong@ccmu.edu.cn.
⁶ Beijing Key Laboratory of Diabetes Research and Care, Beijing, China. zhaodong@ccmu.edu.cn.

^# Contributed equally.

Abstract

Background: AK098656 may be an adverse factor for coronary heart disease (CHD), especially in patients with hypertension. This study aimed to analyze the effect of AK098656 on CHD and CHD with various complications.

Methods: A total of 117 CHD patients and 27 healthy control subjects were enrolled in the study. Plasma AK098656 expression was determined using the quantitative real-time polymerase chain reaction. Student's t-test was used to compare AK098656 expression levels in different groups. Receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to quantify the discrimination ability between CHD patients and health controls and between CHD and CHD + complications patients. The relationship between AK098656 and coronary stenosis was analyzed using Spearman's correlation.

Results: AK098656 expression was remarkably higher in CHD patients than in healthy controls (P = 0.03). The ROC curve revealed an effective predictive AK098656 expression value for CHD risk, with an AUC of 0.656 (95% CI 0.501-0.809). Moreover, AK098656 expression was increased in CHD + complications patients compared to CHD patients alone (P = 0.005), especially in patients with hypertension (CHD + hHTN, P = 0.030). The ROC curve revealed a predictive AK098656 prognostic value for discriminating between CHD and CHD + hHTN patients, with an AUC of 0.666 (95% CI 0.528-0.805). There was no significant difference in AK098656 expression in CHD patients with diabetes mellitus compared to CHD patients alone. In addition, AK098656 expression in CHD patients was positively correlated with stenosis severity (R = 0.261, P = 0.006).

Conclusion: AK098656 expression was significantly increased in patients with CHD, especially those with hypertension, and its expression level was positively correlated with the degree of coronary stenosis. This implied that AK098656 may be a risk factor for CHD and can potentially be applied in clinical diagnosis or provide a novel target for treatment.

Keywords: AK098656; Complications; Coronary heart disease; Hypertension; Stenosis.

Abstract

Grants and funding